Developer docs
API playgroundTry for free, no card

Search company profiles

Frontage Laboratories

Full company profile

uuid0002ryh

Namestring
Frontage Laboratories
Legal namestring
Frontage Laboratories, Inc.
Websiteurl
frontagelab.com
Company typeenum
Public
Founded yearint
2001
Descriptiontext

Frontage Laboratories is a global Contract Research, Development, and Manufacturing Organization (CRDMO) founded in 2001 and headquartered in Exton, Pennsylvania, with approximately 2,200 employees across 28 sites in North America, Asia-Pacific, and Europe. The company is publicly traded (Frontage Holdings Corporation, ticker hkg:1521) and operates under a horizontal B2B services model, serving pharmaceutical and biotechnology clients across the full drug development lifecycle. Service offerings span Drug Discovery Services (GDDS), Drug Development including DMPK and Safety/Toxicology, Clinical Services, Laboratory Testing Services (bioanalytical, central lab, genomics, biomarkers), and CMC product development and manufacturing. The portfolio has been expanded through acquisitions of Nucro-Technics (Canada, 2023), Accelera S.r.l. bioanalytical and DMPK businesses (Europe, 2024), and Teddy Clinical Research Laboratory (China, 2026), positioning Frontage as an integrated one-stop shop.

The company generates revenue through project-based, multi-year B2B contracts negotiated on scope, complexity, and timeline with pharmaceutical, biotechnology, generic drug, and agrochemical clients. Its technology stack includes proprietary assets such as the FRONTAGEMATRIX Logistic System for clinical trial sample tracking and kitting, and integrated LabVantage LIMS with EDC interoperability, alongside advanced analytical platforms including Quanterix Simoa HD-X for femtogram-level biomarker detection and Gyrolab for high-throughput immunoassays. The 2025 opening of a GMP manufacturing facility in Exton, Pennsylvania (validation completed October 2025) and the January 2026 launch of a 160-bed Phase I clinical unit in Secaucus, New Jersey have extended the platform from research services into clinical manufacturing and early-phase execution. Go-to-market is enterprise field sales with active participation in industry conferences (AAPS, WRIB, AACR, ACS, STP, ACT) and a content-driven marketing approach via the corporate website, resource library, LinkedIn, and YouTube channels. The company holds CAP accreditation, NGSP Level 1 certification, and IEC 27001:2022 certification, with 200+ successful FDA inspections cited as a regulatory track record.

Short descriptiontext

Frontage Laboratories is a global public CRDMO providing integrated drug discovery, development, bioanalytical, clinical, and CMC manufacturing services to pharmaceutical and biotechnology clients across 28 sites and approximately 2,200 employees in North America, Europe, and Asia-Pacific.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersExton, United States
HQ citystring
Exton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract research organization, drug development services, bioanalytical testing services, clinical research services, pharmaceutical contract manufacturing
Industry6 codes
PRIMARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAFAMAL
Clinical Research & Trial Central Laboratories
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code4 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Laboratories621511
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Scientific Research and Development Services5417
SIC code3 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
  • Services-Testing Laboratories8734
Product category
Contract Research and Development Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Research Services
TypeProfessional Services
Description

B2B contract research organization (CRO) providing fee-for-service research across drug discovery, drug development, bioanalytical services, central lab services, and DMPK. Revenue generated through project-based contracts with pharmaceutical and biotech companies.

frontagelab.com
2Contract Development and Manufacturing (CDMO)
TypeManaged Services
Description

CMC product development and manufacturing services including drug substance development, formulation development, clinical trial material (CTM) manufacturing, and commercial manufacturing. Revenue from GMP manufacturing contracts.

frontagelab.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
Pricing details1 tier
1Project-based contract pricing for pharmaceutical/biotech clients
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing is negotiated on a project-by-project basis depending on service scope, therapeutic area complexity, regulatory requirements, and timeline. No standard pricing tiers publicly disclosed.

frontagelab.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1FRONTAGEMATRIX LOGISTIC SYSTEM™
Description

Clinical trial logistics services system including kitting, supply chain management, digital sample tracking, and global distribution capabilities.

frontagelab.com
Core offering1 text field

Frontage Laboratories is a global Contract Research, Development and Manufacturing Organization (CRDMO) providing integrated, science-driven drug development services across the full lifecycle. Its offerings span drug discovery (chemistry, biology, ADME/Tox screening, pharmacology), drug development (DMPK, safety assessment/toxicology, early-phase clinical services), laboratory testing (bioanalytical for small and large molecules, central lab, genomics, biomarkers and precision medicine), and CMC product development and GMP manufacturing for drug substance, formulation, clinical trial materials, and commercial supply.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Supported over 1,500 clinical trials contributing to regulatory approval of 50 new drugs
+3 more records
Product overview1 text field

Frontage Laboratories is a global Contract Research Organization (CRO) operating as a fully integrated CRDMO (Contract Research, Development and Manufacturing Organization) with 28 sites across North America, Asia-Pacific, and Europe and approximately 2,200 employees. The company offers an integrated 'one-stop shop' model spanning Drug Discovery Services (GDDS), Drug Development (DMPK, Safety & Toxicology, Clinical Services), Laboratory Testing Services (Bioanalytical, Central Lab, Genomics, Biomarkers & Precision Medicine), and CMC – Product Development & Manufacturing. The portfolio includes its own internal platforms (LabVantage LIMS, FRONTAGEMATRIX Logistic System) and has been expanded through acquisitions including Nucro-Technics (Canada, analytical chemistry/microbiology/toxicology), Accelera S.r.l. (bioanalytical and DMPK), and Teddy Clinical Research Laboratory (China, central lab services). A key infrastructure asset is the GMP manufacturing facility in Exton, PA opened in 2025. The company also offers dedicated Agrochemical Services in GLP-compliant facilities.

Product and service10 records
1Drug Discovery Services (GDDS)
CategoryDrug Discovery Services
Description

End-to-end drug discovery services covering custom synthesis, medicinal chemistry, process chemistry and manufacturing, discovery biology, ADME/Tox screening, and pharmacology; helps pharmaceutical and biotech sponsors generate hits and leads and advance compounds to IND candidacy.

2Drug Metabolism & Pharmacokinetics (DMPK)
CategoryDrug Development Services
Description

Comprehensive DMPK services including in vitro assays (drug-drug interaction, enzyme kinetics, metabolite profiling, permeability and transporters, protein binding) and in vivo studies (pharmacokinetics, MIST, radiolabeled studies, QWBA, human C14 AME studies) for pharmaceutical and biotech sponsors.

3Safety Assessment & Toxicology
CategoryDrug Development Services
Description

Preclinical safety and toxicology services including safety pharmacology, genetic toxicology, general toxicology, developmental and reproductive toxicology (DART), global pathology services, toxicokinetics, and Standard for Exchange of Nonclinical Data (SEND) data services for pharmaceutical and biotech sponsors.

4Clinical Services
CategoryClinical Research Services
Description

Early phase clinical research capabilities including a 160-bed Phase I clinical unit in Secaucus, New Jersey, C14-hAME studies with onsite nuclear pharmacy, oncology Phase I trials, biometrics (biostatistics, data management, medical writing, statistical programming), and bioequivalence programs for pharmaceutical, biotech, and generic drug sponsors.

5Bioanalytical Services - Small & Large Molecules
CategoryLaboratory Testing Services
Description

Bioanalytical testing for small molecules (mass spectrometry) and large molecules (biologics and bioassays) including method development and validation, ADC, cell and gene therapy, flow cytometry, LBA, automation, PK/TK studies, immunogenicity, sample management, and FTE services for pharmaceutical and biotech sponsors.

6Central Lab Services
CategoryLaboratory Testing Services
Description

Comprehensive central laboratory services including histology and pathology, safety testing, specialty lab testing, biorepository services, clinical sample processing, clinical trial logistics via the FRONTAGEMATRIX Logistic System, biospecimen data services, and central lab e-portal for global clinical trial sponsors.

7Genomics Services
CategoryLaboratory Testing Services
Description

Genomics testing including oncology services (ctDNA analysis, NGS oncology panel), pharmacogenetics, metagenomics and microbiome analysis, and genomic services for clinical biomarker profiling for pharmaceutical and biotech sponsors.

8Biomarkers & Precision Medicine
CategoryLaboratory Testing Services
Description

Biomarker assay development and validation using Quanterix Simoa HD-X (femtogram/mL detection), ELISA, ECL-based assays, Gyrolab high-throughput immunoassays, and multiplexed NULISAseq panels for clinical biomarker profiling across disease areas including Alzheimer's disease, oncology, and neuroscience for biopharma sponsors.

9CMC - Product Development & Manufacturing
CategoryContract Manufacturing (CDMO)
Description

Full-spectrum CDMO services covering drug substance development and manufacturing, product development (formulation, CTM manufacturing, commercial manufacturing), analytical services (small molecule and microbiological), and biologics, cell and gene therapy services, GMP routine testing, and stability programs for pharmaceutical and biotech sponsors.

10Agrochemical Services
CategoryLaboratory Testing Services
Description

Support for agrochemical industry clients including biological, chemical, and regulatory support in GLP-compliant facilities for crop protection product development.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-11
Description

LabConnect opened a new central laboratory facility in Wuxi, China in collaboration with Teddy Laboratory (now part of Frontage Laboratories). The facility supports clinical trial services including custom kit building, sample tracking, logistics, and biorepository services. This expansion enables LabConnect to serve both multinational companies entering the China market and Chinese companies expanding internationally.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-09-23
Description

Strategic collaboration to strengthen global clinical trial capabilities, enhancing service offerings in clinical trial support and laboratory services across regions.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-04-28
Description

Collaboration in early phase clinical trials, enabling expanded capabilities in Phase I clinical research services through partnership with regional hospitals and clinical networks.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-12
Description

Strategic collaboration to expand global genomic testing services, combining Frontage's genomics capabilities with Medicover's clinical trial network to provide integrated solutions for pharmaceutical and biotech clients worldwide.

Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries6 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance8 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A7 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frontage Laboratories

Contract Research and Development Servicesfrontagelab.com

Frontage Laboratories is a global public CRDMO providing integrated drug discovery, development, bioanalytical, clinical, and CMC manufacturing services to pharmaceutical and biotechnology clients across 28 sites and approximately 2,200 employees in North America, Europe, and Asia-Pacific.

What Frontage Laboratories does

Frontage Laboratories is a global Contract Research, Development, and Manufacturing Organization (CRDMO) founded in 2001 and headquartered in Exton, Pennsylvania, with approximately 2,200 employees across 28 sites in North America, Asia-Pacific, and Europe. The company is publicly traded (Frontage Holdings Corporation, ticker hkg:1521) and operates under a horizontal B2B services model, serving pharmaceutical and biotechnology clients across the full drug development lifecycle. Service offerings span Drug Discovery Services (GDDS), Drug Development including DMPK and Safety/Toxicology, Clinical Services, Laboratory Testing Services (bioanalytical, central lab, genomics, biomarkers), and CMC product development and manufacturing. The portfolio has been expanded through acquisitions of Nucro-Technics (Canada, 2023), Accelera S.r.l. bioanalytical and DMPK businesses (Europe, 2024), and Teddy Clinical Research Laboratory (China, 2026), positioning Frontage as an integrated one-stop shop.

The company generates revenue through project-based, multi-year B2B contracts negotiated on scope, complexity, and timeline with pharmaceutical, biotechnology, generic drug, and agrochemical clients. Its technology stack includes proprietary assets such as the FRONTAGEMATRIX Logistic System for clinical trial sample tracking and kitting, and integrated LabVantage LIMS with EDC interoperability, alongside advanced analytical platforms including Quanterix Simoa HD-X for femtogram-level biomarker detection and Gyrolab for high-throughput immunoassays. The 2025 opening of a GMP manufacturing facility in Exton, Pennsylvania (validation completed October 2025) and the January 2026 launch of a 160-bed Phase I clinical unit in Secaucus, New Jersey have extended the platform from research services into clinical manufacturing and early-phase execution. Go-to-market is enterprise field sales with active participation in industry conferences (AAPS, WRIB, AACR, ACS, STP, ACT) and a content-driven marketing approach via the corporate website, resource library, LinkedIn, and YouTube channels. The company holds CAP accreditation, NGSP Level 1 certification, and IEC 27001:2022 certification, with 200+ successful FDA inspections cited as a regulatory track record.

Frontage Laboratories firmographics

Firmographics
Name
Frontage Laboratories
Legal name
Frontage Laboratories, Inc.
Website
https://frontagelab.com
Company type
Public
Founded year
2001
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Frontage Laboratories is a global public CRDMO providing integrated drug discovery, development, bioanalytical, clinical, and CMC manufacturing services to pharmaceutical and biotechnology clients across 28 sites and approximately 2,200 employees in North America, Europe, and Asia-Pacific.
Ownership category
akta.pro rank

Frontage Laboratories industry classification

Industry
Product category
Contract Research and Development Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Services-Testing Laboratories (8734)
akta.pro industry
PRIMARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAFAMAL
Clinical Research & Trial Central Laboratories
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Contract research organization
  • Drug development services
  • Bioanalytical testing services
  • Clinical research services
  • Pharmaceutical contract manufacturing

Where Frontage Laboratories is headquartered

Location

Headquarters

HQ city
Exton
HQ country
United States
HQ region
North America

Offices7 records

Markets served

Frontage Laboratories business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. Contract Research Services: B2B contract research organization (CRO) providing fee-for-service research across drug discovery, drug development, bioanalytical services, central lab services, and DMPK. Revenue generated through project-based contracts with pharmaceutical and biotech companies.
  2. Contract Development and Manufacturing (CDMO): CMC product development and manufacturing services including drug substance development, formulation development, clinical trial material (CTM) manufacturing, and commercial manufacturing. Revenue from GMP manufacturing contracts.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractProject-based contract pricing for pharmaceutical/biotech clients

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Frontage Laboratories product offering

Product offering

Core offering

Frontage Laboratories is a global Contract Research, Development and Manufacturing Organization (CRDMO) providing integrated, science-driven drug development services across the full lifecycle. Its offerings span drug discovery (chemistry, biology, ADME/Tox screening, pharmacology), drug development (DMPK, safety assessment/toxicology, early-phase clinical services), laboratory testing (bioanalytical for small and large molecules, central lab, genomics, biomarkers and precision medicine), and CMC product development and GMP manufacturing for drug substance, formulation, clinical trial materials, and commercial supply.

Product overview

Frontage Laboratories is a global Contract Research Organization (CRO) operating as a fully integrated CRDMO (Contract Research, Development and Manufacturing Organization) with 28 sites across North America, Asia-Pacific, and Europe and approximately 2,200 employees. The company offers an integrated 'one-stop shop' model spanning Drug Discovery Services (GDDS), Drug Development (DMPK, Safety & Toxicology, Clinical Services), Laboratory Testing Services (Bioanalytical, Central Lab, Genomics, Biomarkers & Precision Medicine), and CMC – Product Development & Manufacturing. The portfolio includes its own internal platforms (LabVantage LIMS, FRONTAGEMATRIX Logistic System) and has been expanded through acquisitions including Nucro-Technics (Canada, analytical chemistry/microbiology/toxicology), Accelera S.r.l. (bioanalytical and DMPK), and Teddy Clinical Research Laboratory (China, central lab services). A key infrastructure asset is the GMP manufacturing facility in Exton, PA opened in 2025. The company also offers dedicated Agrochemical Services in GLP-compliant facilities.

Differentiator

Problem solved

Functional benefit

Brands

  • FRONTAGEMATRIX LOGISTIC SYSTEM™: Clinical trial logistics services system including kitting, supply chain management, digital sample tracking, and global distribution capabilities.

Products and services

  • Drug Discovery Services (GDDS) End-to-end drug discovery services covering custom synthesis, medicinal chemistry, process chemistry and manufacturing, discovery biology, ADME/Tox screening, and pharmacology; helps pharmaceutical and biotech sponsors generate hits and leads and advance compounds to IND candidacy.
  • Drug Metabolism & Pharmacokinetics (DMPK) Comprehensive DMPK services including in vitro assays (drug-drug interaction, enzyme kinetics, metabolite profiling, permeability and transporters, protein binding) and in vivo studies (pharmacokinetics, MIST, radiolabeled studies, QWBA, human C14 AME studies) for pharmaceutical and biotech sponsors.
  • Safety Assessment & Toxicology Preclinical safety and toxicology services including safety pharmacology, genetic toxicology, general toxicology, developmental and reproductive toxicology (DART), global pathology services, toxicokinetics, and Standard for Exchange of Nonclinical Data (SEND) data services for pharmaceutical and biotech sponsors.
  • Clinical Services Early phase clinical research capabilities including a 160-bed Phase I clinical unit in Secaucus, New Jersey, C14-hAME studies with onsite nuclear pharmacy, oncology Phase I trials, biometrics (biostatistics, data management, medical writing, statistical programming), and bioequivalence programs for pharmaceutical, biotech, and generic drug sponsors.
  • Bioanalytical Services - Small & Large Molecules Bioanalytical testing for small molecules (mass spectrometry) and large molecules (biologics and bioassays) including method development and validation, ADC, cell and gene therapy, flow cytometry, LBA, automation, PK/TK studies, immunogenicity, sample management, and FTE services for pharmaceutical and biotech sponsors.
  • Central Lab Services Comprehensive central laboratory services including histology and pathology, safety testing, specialty lab testing, biorepository services, clinical sample processing, clinical trial logistics via the FRONTAGEMATRIX Logistic System, biospecimen data services, and central lab e-portal for global clinical trial sponsors.
  • Genomics Services Genomics testing including oncology services (ctDNA analysis, NGS oncology panel), pharmacogenetics, metagenomics and microbiome analysis, and genomic services for clinical biomarker profiling for pharmaceutical and biotech sponsors.
  • Biomarkers & Precision Medicine Biomarker assay development and validation using Quanterix Simoa HD-X (femtogram/mL detection), ELISA, ECL-based assays, Gyrolab high-throughput immunoassays, and multiplexed NULISAseq panels for clinical biomarker profiling across disease areas including Alzheimer's disease, oncology, and neuroscience for biopharma sponsors.
  • CMC - Product Development & Manufacturing Full-spectrum CDMO services covering drug substance development and manufacturing, product development (formulation, CTM manufacturing, commercial manufacturing), analytical services (small molecule and microbiological), and biologics, cell and gene therapy services, GMP routine testing, and stability programs for pharmaceutical and biotech sponsors.
  • Agrochemical Services Support for agrochemical industry clients including biological, chemical, and regulatory support in GLP-compliant facilities for crop protection product development.

Quantifiable outcome

  • Supported over 1,500 clinical trials contributing to regulatory approval of 50 new drugs
  • +3 more outcomes

Companies that use Frontage Laboratories

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Frontage Laboratories technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Frontage Laboratories partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • LabConnectcoreStrategic or Co-development Partner · 11 March 2026LabConnect opened a new central laboratory facility in Wuxi, China in collaboration with Teddy Laboratory (now part of Frontage Laboratories). The facility supports clinical trial services including custom kit building, sample tracking, logistics, and biorepository services. This expansion enables LabConnect to serve both multinational companies entering the China market and Chinese companies expanding internationally.
  • GCCL (Global Central Lab)minorStrategic or Co-development Partner · 23 September 2025Strategic collaboration to strengthen global clinical trial capabilities, enhancing service offerings in clinical trial support and laboratory services across regions.
  • EPNextS GroupminorStrategic or Co-development Partner · 28 April 2025Collaboration in early phase clinical trials, enabling expanded capabilities in Phase I clinical research services through partnership with regional hospitals and clinical networks.
  • Medicover Integrated Clinical ServicescoreStrategic or Co-development Partner · 12 November 2024Strategic collaboration to expand global genomic testing services, combining Frontage's genomics capabilities with Medicover's clinical trial network to provide integrated solutions for pharmaceutical and biotech clients worldwide.

Scale indicators8 records

Recent moves11 records

Expansion highlights7 records

Frontage Laboratories competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Frontage Laboratories social profiles

Digital presence

Frontage Laboratories compliance and trust

Trust signal

Compliance8 records

Frontage Laboratories financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Frontage Laboratories leadership team

Management profile

Number of profiles

Profiles9 records

Frontage Laboratories subsidiaries and ownership

Company hierarchy

Subsidiaries6 records

Frontage Laboratories funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Frontage Laboratories M&A and investment

M&A and investment

M&A7 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Frontage Laboratories

What does Frontage Laboratories do?

Frontage Laboratories is a global Contract Research, Development and Manufacturing Organization (CRDMO) providing integrated, science-driven drug development services across the full lifecycle. Its offerings span drug discovery (chemistry, biology, ADME/Tox screening, pharmacology), drug development (DMPK, safety assessment/toxicology, early-phase clinical services), laboratory testing (bioanalytical for small and large molecules, central lab, genomics, biomarkers and precision medicine), and CMC product development and GMP manufacturing for drug substance, formulation, clinical trial materials, and commercial supply.

Is Frontage Laboratories a public or private company?

Frontage Laboratories is a public company. It is classified as public and is currently operating.

When was Frontage Laboratories founded?

Frontage Laboratories was founded in 2001. It employs 501 to 1,000 people.

Where is Frontage Laboratories based?

Frontage Laboratories is headquartered in Exton, United States, in the North America region.

How does Frontage Laboratories make money?

Two revenue lines are on record. Contract Research Services are the primary driver. The others are contract Development and Manufacturing (CDMO).

Does Frontage Laboratories have an API?

No public API is recorded for Frontage Laboratories.

What industry is Frontage Laboratories in?

Frontage Laboratories's product category is Contract Research and Development Services. Its primary akta.pro industry code is HLAGAAAC, Toxicology & Safety Assessment CROs (GLP), with a secondary code of HLAGAAAA, Clinical CROs (Phase I–IV). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewFrontage Holdings Corporation Proposes Privatization and Business RestructuringFrontage Holdings proposed privatization from HKEX and restructuring, dividing its businesses among Charles River Laboratories, Tigermed, and Chairman Dr. Song Li. The transaction requires shareholder and regulatory approvals, with no transaction value or timetable disclosed.Pharmaceutical TechnologyCharles River agrees $470m deal for Frontage assetsCharles River agreed to acquire Frontage Holdings' Pennsylvania bioanalysis and DMPK operations for about $470m in cash, with potential payments up to $75m. The assets generated 40% of Frontage's 2025 revenue of $256.7m. The deal is expected to close in the first half of 2027.PR Newswire APACTigermed to Participate in the Privatization of Frontage Holdings Corporation and Divest Its Overseas Laboratory Services BusinessTigermed proposed to privatize its subsidiary Frontage Holdings and divest its overseas laboratory services business to Charles River and Dr. Song Li, retaining China operations. The move aims to focus on clinical CRO, optimize capital allocation, and generate investment gains for shareholders.PR NewswireTigermed to Participate in the Privatization of Frontage Holdings Corporation and Divest Its Overseas Laboratory Services BusinessTigermed proposed to privatize its subsidiary Frontage Holdings and divest Frontage's overseas laboratory services business to Charles River Laboratories and Dr. Song Li, retaining China operations. The move aims to focus on clinical CRO, optimize capital allocation, and generate proceeds for shareholder value.LinkedInFrontage Laboratories, IncFrontage Laboratories, a US-based contract research organization, was founded in 2001 and moved to Pennsylvania in 2004. It operates 26 facilities across multiple countries and offers services including drug discovery, clinical trials, and formulation development. The company has supported biotech and pharma firms in regulatory submissions.PR NewswireFrontage Laboratories Is Pleased to Welcome Dr. Chandra Prakash, Ph.D., as Senior Advisor, Clinical ServicesFrontage Laboratories has appointed Dr. Chandra Prakash, Ph.D. as Senior Advisor, Clinical Services, bringing four decades of expertise in drug metabolism, pharmacokinetics, and clinical pharmacology. Dr. Prakash previously held senior scientific leadership roles at major pharmaceutical companies including Agios Pharmaceuticals, Biogen, and Pfizer, and has contributed to numerous successful regulatory submissions and approved therapies. In this advisory capacity, he will provide strategic guidance on clinical pharmacology study design, human ADME programs, PBPK modeling, and regulatory submissions to support Frontage's expanding clinical services operations.openPR.comEmerging Growth Patterns Driving Expansion in the Central Lab MarketThe central laboratory market is projected to reach $4.83 billion by 2030, growing at a compound annual growth rate of 7.8%, driven by precision medicine funding, AI-based lab analytics, decentralized clinical trials, and increased demand for integrated laboratory services. In August 2023, Frontage Laboratories, Inc., a U.S.-based pharmaceutical company, acquired Nucro-Technics Inc. and Nucro-Technics Holdings, Inc., Canadian contract support organizations, to expand its drug development and clinical research capabilities. The market is also seeing innovation in patient-friendly solutions, exemplified by Dentsply Sirona's November 2023 launch of 3D printing dental splint resins.Pulse 2.0Frontage Laboratories: Acquisition Of Teddy Clinical Research LaboratoryFrontage Laboratories has completed the acquisition of Teddy Clinical Research Laboratory (Shanghai), Ltd., a clinical research laboratory service provider based in China. The deal is intended to expand Frontage's global laboratory service capabilities and strengthen its presence in China and the broader Asia-Pacific region. Teddy Lab has supported over 1,500 clinical trials and contributed to regulatory approval of more than 50 new drugs, operating under CAP-accredited and NGSP Level 1 certified quality systems.ContractpharmaFrontage Labs Completes Acquisition of Teddy LabFrontage Laboratories, Inc. has completed the acquisition of Teddy Clinical Research Laboratory (Shanghai), Ltd. (Teddy Lab), a clinical research laboratory service provider in China, to enhance its global laboratory service capabilities and strengthen its presence in the China and Asia-Pacific region. Teddy Lab has supported more than 1,500 clinical trials across multiple therapeutic areas and contributed to the successful marketing approval of 50 new drugs, operating under CAP-accredited and NGSP Level 1 certified quality systems. The transaction expands Frontage's central laboratory footprint in China and supports increasing demand for domestic and multi-regional clinical trials.